ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1257

Subclinical Atherosclerosis in Hispanic Patients with Rheumatoid Arthritis. Correlation with the Presence of Anti-Oxidized LDL Antibodies and Serum Levels of CD40L

Yurilis Fuentes-Silva1, Soham Al Snih2, Natali Serra-Bonett1, Juan De Sanctis3 and Martin A. Rodriguez4, 1Rheumatology, Centro Nacional de Enfermedades Reumáticas, Caracas, Venezuela, 2Division of Rehabilitation Sciences, Division of Geriatrics. Sealy Center on Aging, University of Texas Medical Branch, Galveston, TX, 3Immunology, Instituto de Inmunología, Caracas, Venezuela, 4Centro Nacional de Enfermedades Reumáticas, Hospital Universitario de Caracas, Caracas, Venezuela

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Biomarkers, Cardiovascular disease and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects II: Clinical Features & Comorbidity/Cardiovascular Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease, associated with an excess of cardiovascular morbidity and mortality due to accelerated atherosclerosis. The appearance of antibodies (Abs) against anti-oxLDL may be a pathogenic link between inflammation and atherosclerosis. An excessive CD40L/CD40 interaction is thought to play a pathogenic role in RA. The aim of this study was to search for the presence of subclinical atherosclerosis in a group of Venezuelan patients with RA and examine its correlation with anti-oxLDL Abs and serum levels of CD40L. 

Methods: Sixty-five RA patients and 26 healthy volunteers participated in the study. The presence and total serum levels of anti-oxLDL Abs and CD40L were examined by ELISA. The  biologically active CD40L was measured by an assay testing induction of nitric oxide production in vitro by RAW mouse 264.7 cells. The presence of subclinical atherosclerosis was detected by the measurement of intima-media-thickness (IMT) of the common carotid arteries using a Doppler ultrasound system (Esaote MyLab, 12 Mhz). Subclinical atherosclerosis was defined by an IMT ≥ 0.6 mm.  Statistical analysis was performed by Student´s t test and Chi-square and the Exact Fisher´s test for continuous and dichotomous variables, respectively. The study was approved by our hospital Ethics Committee and all patients signed an informed consent.

Results: We compared 65 RA patients (92.3% female; mean age 50,58±8,96) with 26 healthy controls (96.15% female; mean age 43.42±9.62). DMARDs and DMARDs plus biologics were received by 98.46% and 18.46% of patients, respectively. Mean disease duration was 7.32±6.04 years and mean and Disease Activity Score (DAS) 28-ESR was 3.19±1.5. Serum levels of anti-oxLDL were significantly higher in the RA patients than in healthy controls (34.48±9.83 vs. 24.74±6.4; P= 0,01). Serum levels of total CD40L and biologically active CD40L were also significantly higher in RA patients than in controls (9.13±2.74 vs. 3.86±1.21; P < 0,0001 and 3.81±1.94 vs. 1.6±1.11; P = 0,002). Patients with RA showed a higher proportion of an IMT ≥ 0.6 mm (P = 0,006). There was no correlation between serum levels of anti-oxLDL or CD40L with IMT.

Conclusion: To our knowledge this is the first study showing the presence of subclinical atherosclerosis in Hispanic patients with RA. Elevated serum titers of anti-oxLDL Abs and both total and soluble CD40L were features observed in this patient population suggesting their potential utility as biomarkers in this disease. Our preliminary results do not support a role for anti-oxLDL Abs or CD40L in the premature atherosclerosis observed in RA patients.


Disclosure:

Y. Fuentes-Silva,
None;

S. Al Snih,
None;

N. Serra-Bonett,
None;

J. De Sanctis,
None;

M. A. Rodriguez,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/subclinical-atherosclerosis-in-hispanic-patients-with-rheumatoid-arthritis-correlation-with-the-presence-of-anti-oxidized-ldl-antibodies-and-serum-levels-of-cd40l/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology